Precision Medicine Division Using AI, Big Data and Predictive Technologies Launched
Learn More
NovAccess Global to Present at World Orphan Drug Congress
Learn More
NovAccess Leaders Presented at 2023 SBMT Conference
Learn More
FDA Approves Orphan Drug Designation for TLR-AD1
Learn More
Recent Uplist to OTCQB
Learn More
Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
Discovery to Science-Led Public Company
Learn More
Previous slide
Next slide
Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
The Journey from Discovery to IPO
Learn More
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous slide
Next slide
FDA Approves Orphan Drug Designation
Recent Uplist to OTCQB
Recent Uplist to OTCQB
Learn More
Board of Directors Expanded
Patented Immunotherapy Candidate
The Journey from Discovery to IPO
The Journey from Discovery to IPO
Learn More
Previous slide
Next slide

Our patented approach, TLR-AD1 seeks to bolster the body’s immune system through cellular training; strengthening the body’s defense against cancer.

Press
All
NovAccess Global Press Releases
NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform
NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform
 NovAccess Global Advisory on Annual Meeting of Shareholders 
 NovAccess Global Advisory on Annual Meeting of Shareholders 
NovAccess Global Announces New License to Advance its Immunotherapy Platform
NovAccess Global Announces New License to Advance its Immunotherapy Platform
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
NovAccess Global Announces $10.7 Million Financing
NovAccess Global Announces $10.7 Million Financing
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit

With TLR-AD1, we will provide Novel Access to the Global market.

Learn About TLR-AD1

Join Us

Submit